Liquidia Corporation
MUN:LT4 Rapport sur les actions
Capitalisation boursière : €852.6m
Liquidia Bilan de santé
Santé financière contrôle des critères 4/6 Liquidia possède un total de capitaux propres de $62.7M et une dette totale de $85.9M, ce qui porte son ratio d'endettement à 137%. Son actif total et son passif total sont $177.4M et de $114.6M.
Informations clés
137.0%
Ratio d'endettement
Ratio de couverture des intérêts n/a Argent liquide US$133.09m Fonds propres US$62.72m Total du passif US$114.64m Total des actifs US$177.36m
Mises à jour récentes de la santé financière
Afficher toutes les mises à jour
Liquidia Corporation to Report Q3, 2024 Results on Nov 13, 2024 Nov 06
Liquidia Corporation to Report Q3, 2024 Results on Nov 11, 2024 Nov 04
Insufficient new directors Oct 03
Liquidia Corporation Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting Oct 01 Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million. Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million. Sep 11
No longer forecast to breakeven Aug 28
Insufficient new directors Aug 28
Liquidia Corporation Files Litigation to Challenge Regulatory Exclusivity Blocking Access to Yutrepia (Treprostinil) Inhalation Powder for Patients Suffering with PAH and PH-ILD Aug 22
Liquidia Corporation Announces U.S. Food and Drug Administration Grants Tentative Approval of YUTPIA®? (Treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Aug 19
Liquidia Corporation to Report Q2, 2024 Results on Aug 07, 2024 Jul 31
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch Jun 05
First quarter 2024 earnings released: US$0.54 loss per share (vs US$0.18 loss in 1Q 2023) May 15
New minor risk - Profitability May 14
No longer forecast to breakeven May 14
Liquidia Corporation to Report Q1, 2024 Results on May 14, 2024 May 09
Liquidia Corporation, Annual General Meeting, Jun 20, 2024 May 01
Liquidia Corporation Provides Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA Approval of YUTREPIA™ (treprostinil) Inhalation Powder Apr 02
CEO & Director recently sold €416k worth of stock Mar 21
Full year 2023 earnings released: US$1.21 loss per share (vs US$0.67 loss in FY 2022) Mar 14
Insufficient new directors Mar 07
Liquidia Corporation to Report Fiscal Year 2023 Results on Mar 13, 2024 Mar 07
Insufficient new directors Jan 25
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA (Treprostinil) Inhalation Powder Jan 25
Liquidia Corporation Announces the Launch of Yutrepiatm (Treprostinil) Inhalation Powder Jan 20
Liquidia Corporation Announces Updates to Operations Leadership Jan 19 Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims Liquidia Corporation announced that it expects to receive $74.999999 million in funding from Legend Aggregator, LP Liquidia Corporation announced that it expects to receive $74.999999 million in funding from Legend Aggregator, LP Jan 05
Insufficient new directors Jan 02
Forecast to breakeven in 2026 Dec 31
Independent Director recently bought €1.8m worth of stock Dec 22 Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $24.999999 million. Liquidia Corporation has filed a Follow-on Equity Offering in the amount of $24.999999 million.
Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.14 loss in 3Q 2022) Nov 11
Liquidia Corporation to Report Q3, 2023 Results on Nov 07, 2023 Nov 01
FDA Accepts Liquidia Corporation's Submission to Add PH-ILD to YUTREPIA™ Label Sep 26
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office Sep 08
Liquidia Corporation to Report Q2, 2023 Results on Aug 10, 2023 Aug 04
Liquidia Corporation Submits Amendment to Add Ph-Ild Indication to Tentatively Approved Nda for Yutpia (Treprostinil) Inhalation Powder Jul 28
Liquidia Corporation Announces U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation Jul 25
Liquidia Corporation to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
CEO & Director recently bought €246k worth of stock Sep 09 Liquidia Corporation Provides Update on Hatch-Waxman Litigation
High number of new directors Aug 30
Analyse de la situation financière
Passif à court terme: Les actifs à court terme de LT4 ( $147.3M ) dépassent ses passifs à court terme ( $24.2M ).
Passif à long terme: Les actifs à court terme de LT4 ( $147.3M ) dépassent ses passifs à long terme ( $90.4M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: LT4 dispose de plus de liquidités que de sa dette totale.
Réduire la dette: Le ratio d'endettement de LT4 est passé de 49.4% à 137% au cours des 5 dernières années.
Analyse des pistes de trésorerie Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: LT4 dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.
Prévisions de trésorerie: Données insuffisantes pour déterminer si LT4 dispose de suffisamment de piste de trésorerie si son flux de trésorerie disponible continue de croître ou de diminuer en fonction des taux historiques.
Découvrir des entreprises saines Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}